» Articles » PMID: 35309272

A Prospective Six-month Single-blind Study Evaluating Changes in Hair Growth and Quality Using a Nutraceutical Supplement in Men and Women of Diverse Ethnicities

Overview
Date 2022 Mar 21
PMID 35309272
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The goal of this study was to assess the perceived efficacy of a standardized nutraceutical to improve hair growth and quality in men and women of various ethnicities with self-perceived hair thinning.

Methods: This prospective, single-blind study enrolled healthy men aged 20 to 55 years (n=47) and premenopausal women aged 20 to 45 years (n=51) with self-perceived, mild-to-moderate hair thinning and included African American, Asian, Hispanic Caucasian and Non-Hispanic Caucasian participants. The nutraceutical supplement (Nutrafol® Men or Women Capsules, Nutraceutical Wellness Inc., New York, New York) was taken daily for six months. Subjects were evaluated in the clinic at baseline and Weeks 12 and 24 with two self-assessments at Weeks 4 and 8. Study endpoints were standardized digital imaging and investigator rated assessments. Self-assessment questionnaires rated hair growth, hair satisfaction, and lifestyle factors.

Results: Investigator ratings for baseline hair growth, coverage, density, and volume were significant at Weeks 12 and 24 for all subjects (for each, <0.001). These significant improvements were seen in 83.7 percent of men and 79.5 percent of women at Week 24. Results were similar across ethnic subgroups with significant benefit at Weeks 12 and 24 (for each, <0.05). All subjects reported significant improvements in baseline hair appearance/quality, volume/fullness, scalp coverage, thickness, and shedding at Weeks 4, 8, 12 and 24 (for each, <0.01).

Conclusion: A standardized nutraceutical supplement improved visible hair growth with less notable shedding based on subjects' and investigators' overall perception of treatment benefit for men and women of various ethnic backgrounds.

Citing Articles

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair.

Bhatia N, Ablon G, Farris P, Hazan A, Raymond I J Cosmet Dermatol. 2025; 24(1):e16778.

PMID: 39757794 PMC: 11701407. DOI: 10.1111/jocd.16778.


Characterization of the role of Facebook groups for patients who use scalp cooling therapy: a survey study.

Rose L, Novice M, Kobayashi S, Minta A, Novice T, Lo Sicco K Support Care Cancer. 2024; 32(6):351.

PMID: 38748328 PMC: 11096238. DOI: 10.1007/s00520-024-08534-y.


Androgenetic Alopecia: Therapy Update.

Devjani S, Ezemma O, Kelley K, Stratton E, Senna M Drugs. 2023; 83(8):701-715.

PMID: 37166619 PMC: 10173235. DOI: 10.1007/s40265-023-01880-x.

References
1.
Tas B, Kulacaoglu F, Belli H, Altuntas M . The tendency towards the development of psychosexual disorders in androgenetic alopecia according to the different stages of hair loss: a cross-sectional study. An Bras Dermatol. 2018; 93(2):185-190. PMC: 5916388. DOI: 10.1590/abd1806-4841.20185658. View

2.
Hirsso P, Rajala U, Laakso M, Hiltunen L, Harkonen P, Keinanen-Kiukaanniemi S . Health-related quality of life and physical well-being among a 63-year-old cohort of women with androgenetic alopecia; a Finnish population-based study. Health Qual Life Outcomes. 2005; 3:49. PMC: 1198244. DOI: 10.1186/1477-7525-3-49. View

3.
Trueb R . Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002; 37(8-9):981-90. DOI: 10.1016/s0531-5565(02)00093-1. View

4.
Banka N, Bunagan M, Shapiro J . Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin. 2012; 31(1):129-40. DOI: 10.1016/j.det.2012.08.003. View

5.
Lee H, Jung S, Patel A, Thompson J, Qureshi A, Cho E . Racial characteristics of alopecia areata in the United States. J Am Acad Dermatol. 2019; 83(4):1064-1070. DOI: 10.1016/j.jaad.2019.06.1300. View